Acceleron Pharma XLRN Merck Tender Offer Analysis 2021

This November 2021 investor presentation from Avoro Capital, which owns approximately 7% of Acceleron Pharma, argues against Merck's $180 per share tender offer, claiming significant undervaluation. The presentation outlines why Acceleron's standalone path offers superior value, highlighting an approaching phase 3 data inflection point and alternative monetization strategies. Avoro proposes potential board changes to position the company for enhanced shareholder value creation.